PURPOSE: Premenopausal women with breast cancer receiving adjuvant chemotherapy are at risk for amenorrhea. The National Surgical Adjuvant Breast and Bowel Project B-30 trial included menstrual history (MH) and quality-of-life (QOL) studies to compare treatments on these outcomes. PATIENTS AND METHODS: Patients were randomly assigned to sequential doxorubicin (A) and cyclophosphamide (C) followed by docetaxel (T; AC→T), concurrent TAC, or AT, which varied in duration (24, 12, 12 weeks, respectively), and use of C. Endocrine therapy was prescribed for women with hormone receptor-positive tumors. MH and QOL were assessed with standardized questionnaires at baseline; cycle 4, day 1; and every 6 months through 24 months. Prespecified analyses examined rates of amenorrhea by treatment arm, the relationship between amenorrhea and QOL, and QOL by treatment arm. RESULTS: Amenorrhea 12 months after random assignment was significantly different between treatment groups: 69.8% for AC→T, 57.7% for TAC, and 37.9% for AT (P < .001). The AT group without tamoxifen had the lowest rate of amenorrhea. QOL was poorer for patients receiving AC→T at 6 months but similar to others by 12 months. Post-treatment symptoms were increased above baseline for all treatments. Multivariable repeated measures modeling demonstrated that treatment arm, time point, age, and tamoxifen use were significantly associated with symptom severity (all P values < .002). CONCLUSION: Amenorrhea rates differed significantly by treatment arm, with the AT arm having the lowest rate. Patients treated with longer duration therapy (AC→T) had greater symptom severity and poorer QOL at 6 months, but did not differ from shorter duration treatments at 12 months.
PURPOSE: Premenopausal women with breast cancer receiving adjuvant chemotherapy are at risk for amenorrhea. The National Surgical Adjuvant Breast and Bowel Project B-30 trial included menstrual history (MH) and quality-of-life (QOL) studies to compare treatments on these outcomes. PATIENTS AND METHODS: Patients were randomly assigned to sequential doxorubicin (A) and cyclophosphamide (C) followed by docetaxel (T; AC→T), concurrent TAC, or AT, which varied in duration (24, 12, 12 weeks, respectively), and use of C. Endocrine therapy was prescribed for women with hormone receptor-positive tumors. MH and QOL were assessed with standardized questionnaires at baseline; cycle 4, day 1; and every 6 months through 24 months. Prespecified analyses examined rates of amenorrhea by treatment arm, the relationship between amenorrhea and QOL, and QOL by treatment arm. RESULTS: Amenorrhea 12 months after random assignment was significantly different between treatment groups: 69.8% for AC→T, 57.7% for TAC, and 37.9% for AT (P < .001). The AT group without tamoxifen had the lowest rate of amenorrhea. QOL was poorer for patients receiving AC→T at 6 months but similar to others by 12 months. Post-treatment symptoms were increased above baseline for all treatments. Multivariable repeated measures modeling demonstrated that treatment arm, time point, age, and tamoxifen use were significantly associated with symptom severity (all P values < .002). CONCLUSION: Amenorrhea rates differed significantly by treatment arm, with the AT arm having the lowest rate. Patients treated with longer duration therapy (AC→T) had greater symptom severity and poorer QOL at 6 months, but did not differ from shorter duration treatments at 12 months.
Authors: B Fisher; P Carbone; S G Economou; R Frelick; A Glass; H Lerner; C Redmond; M Zelen; P Band; D L Katrych; N Wolmark; E R Fisher Journal: N Engl J Med Date: 1975-01-16 Impact factor: 91.245
Authors: M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: David Cella; Stephanie R Land; Chih-Hung Chang; Richard Day; Joseph P Costantino; Norman Wolmark; Patricia A Ganz Journal: Breast Cancer Res Treat Date: 2007-09-13 Impact factor: 4.872
Authors: Jeanne A Petrek; Michelle J Naughton; L Douglas Case; Electra D Paskett; Elizabeth Z Naftalis; S Eva Singletary; Paniti Sukumvanich Journal: J Clin Oncol Date: 2006-02-13 Impact factor: 44.544
Authors: Sandra M Swain; Stephanie R Land; Marcie W Ritter; Joseph P Costantino; Reena S Cecchini; Eleftherios P Mamounas; Norman Wolmark; Patricia A Ganz Journal: Breast Cancer Res Treat Date: 2008-02-27 Impact factor: 4.872
Authors: Patricia A Ganz; Gail A Greendale; Laura Petersen; Barbara Kahn; Julienne E Bower Journal: J Clin Oncol Date: 2003-11-15 Impact factor: 44.544
Authors: Sandra M Swain; Jong-Hyeon Jeong; Charles E Geyer; Joseph P Costantino; Eduardo R Pajon; Louis Fehrenbacher; James N Atkins; Jonathan Polikoff; Victor G Vogel; John K Erban; Priya Rastogi; Robert B Livingston; Edith A Perez; Eleftherios P Mamounas; Stephanie R Land; Patricia A Ganz; Norman Wolmark Journal: N Engl J Med Date: 2010-06-03 Impact factor: 176.079
Authors: Katrina F Trivers; Aliza K Fink; Ann H Partridge; Kutluk Oktay; Elizabeth S Ginsburg; Chunyu Li; Lori A Pollack Journal: Oncologist Date: 2014-06-20
Authors: Hanna Bandos; Joy Melnikow; Donna R Rivera; Sandra M Swain; Keren Sturtz; Louis Fehrenbacher; James L Wade; Adam M Brufsky; Thomas B Julian; Richard G Margolese; Edward C McCarron; Patricia A Ganz Journal: J Natl Cancer Inst Date: 2018-02-01 Impact factor: 13.506
Authors: Deborah J Bowen; Eileen H Shinn; Sophie Gregrowski; Gretchen Kimmick; Laura S Dominici; Elizabeth S Frank; Karen Lisa Smith; Gabrielle Rocque; Kathryn J Ruddy; Teri Pollastro; Michelle Melisko; Tarah J Ballinger; Oluwadamilola M Fayanju; Antonio C Wolff Journal: Cancer Date: 2019-11-19 Impact factor: 6.860
Authors: Rodrigo R Munhoz; Allan A L Pereira; André D Sasse; Paulo M Hoff; Tiffany A Traina; Clifford A Hudis; Ricardo J Marques Journal: JAMA Oncol Date: 2016-01 Impact factor: 31.777